SCHEDULE: Jason Matuszewski Discloses 17.4% Stake in BioStem Technologies
Schedule 13G Filing
Jason Matuszewski has reported beneficial ownership of 3,665,899 shares, representing 17.4% of BioStem Technologies' common stock, as of September 30, 2026.
Summary
- Jason Matuszewski, the reporting person, has disclosed beneficial ownership of 3,665,899 shares of BioStem Technologies, Inc. common stock.
- This ownership stake represents 17.4% of the total outstanding shares as of October 1, 2026.
- The reported shares include directly held stock, exercisable options, and convertible preferred shares.
- The filing excludes restricted stock units and unvested options from the total beneficial ownership calculation.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral to slightly positive filing, primarily due to a significant beneficial ownership stake, but lacking substantial new strategic or financial information.
Positives
- Significant beneficial ownership stake of 17.4% by Jason Matuszewski, indicating substantial investor interest.
- Ownership includes a mix of directly held shares and exercisable options, suggesting potential for increased stake.
- The reporting person has sole voting and dispositive power over all beneficially owned shares.
Negatives
- The filing is a Schedule 13G, which is an informational filing and does not inherently contain new strategic or financial performance data.
- Excludes a considerable number of shares (RSUs and unvested options) from the reported beneficial ownership, which could be a point of interest for future vesting.
Risks
- The filing does not detail specific risks, as it is primarily an ownership disclosure.
- Future vesting of excluded RSUs and options could dilute existing shareholders if not managed strategically.
Future Outlook
The filing does not contain forward-looking statements or guidance. It is an informational disclosure regarding beneficial ownership.
Industry Context
StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and significant individual shareholders to report their holdings. This filing indicates a substantial personal investment in BioStem Technologies by Jason Matuszewski, which could signal confidence in the company's prospects, though it does not provide direct commentary on the company's operational performance.
Stakeholder Impact
- Shareholders: The significant stake held by Jason Matuszewski could influence voting outcomes and strategic decisions.
- Management: May face increased scrutiny or engagement from a major shareholder with a substantial vested interest.
Next Steps
- Monitor future filings from Jason Matuszewski for any changes in beneficial ownership.
- Observe BioStem Technologies' operational and financial performance to assess the impact of significant shareholder stakes.
Key Dates
| Date | Description |
|---|---|
| 2026-09-30 | Date of Event Which Requires Filing of this Statement |
| 2026-10-01 | Date as of which shares of Common Stock were reported as outstanding |
| 2026-10-02 | Date of Issuer's Registration Statement on Form S-1 filing |
| 2026-10-13 | Expiration date for a portion of options to purchase shares |
| 2026-10-24 | Expiration date for fully vested options |
| 2026-11-10 | Date of Certification and Signature |
| 2026-11-29 | Cut-off date for vesting of excluded restricted stock units and options |
| 2032-10-24 | Expiration date for fully vested options |
Keywords
BioStem Technologies, Jason Matuszewski, Schedule 13G, Beneficial Ownership, Common Stock, Investment, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.